[1]吴进锋 何毅辉 林 乐 魏永宝 李 涛 叶烈夫.B7-H3和PD-L1在肾细胞癌组织中的表达及临床意义[J].福建医药杂志,2020,42(02):16-19.
　WU Jinfeng,HE Yihui,LIN Le,et al.Expression and clinical significance of B7-H3 and PD-L1 in renal cell carcinoma[J].FUJIAN MEDICAL JOURNAL,2020,42(02):16-19.
点击复制

B7-H3和PD-L1在肾细胞癌组织中的表达及临床意义()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年02期
页码:
16-19
栏目:
临床研究
出版日期:
2020-04-15

文章信息/Info

Title:
Expression and clinical significance of B7-H3 and PD-L1 in renal cell carcinoma
文章编号:
1002-2600(2020)02-0016-05
作者:
吴进锋 何毅辉 林 乐 魏永宝 李 涛 叶烈夫
福建医科大学省立临床医学院 福建省立医院泌尿外科(福州 350001)
Author(s):
WU Jinfeng;  HE Yihui;  LIN Le;  WEI Yongbao;  LI Tao;  YE Liefu.
Department of Urology, Fujian Provincial Hospital,Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China
关键词:
共刺激分子B7-H3;  程序性死亡因子配体1;  共刺激分子B7-H1;  肾癌
Keywords:
B7-H3;  B7-H1;  PD-L1;  renal cell carcinoma
分类号:
R737.11
文献标志码:
A
摘要:
目的 评估B7-H3和PD-L1在透明细胞性肾细胞癌(clear cell renal cell carcinoma,ccRCC)中的表达,并探讨其临床意义。方法 采用免疫组化方法检测88例ccRCC患者肿瘤标本中PD-L1和B7-H3表达位置及水平,并分析二者表达与患者年龄、性别、肿瘤TNM分期、Furhman分级、是否合并静脉癌栓及远处转移等临床病理参数之间的关系。结果 PD-L1在15例(17.0%)ccRCC中阳性表达,并与肿瘤TNM分期较晚、高Furhman分级、合并静脉癌栓以及合并远处转移等不良临床和病理特征显著关联。B7-H3在21例(23.9%)肿瘤细胞和82例(93.2%)肿瘤血管内皮细胞中阳性表达,肿瘤血管中有26.1%、25%和42.0%分别呈局灶性、中度和弥漫性表达。B7-H3在肿瘤细胞和血管内皮细胞中的表达都与肿瘤的不良侵袭性特征存在显著关联。结论 B7-H3在肾癌细胞组织中表达比PD-L1更高,且在肿瘤血管内皮细胞中广泛表达,并与肾癌的进展密切关联。B7-H3可能是ccRCC潜在的治疗预测因子和多通路治疗靶点。
Abstract:
Objective To evaluate the expression of B7-H3 and PD-L1 in clear cellular renal cell carcinoma and to explore its clinical significance.Methods Detect expression position and level of PD-L1 and B7-H3 in 88 specimens of ccRCC using immunohistochemical method, and analyze the relationship between the expressions and the clinical pathological parameters, such as age, gender, tumor TNM staging, Furhman grading, venous tumor emboli and distant metastasis.Results PD-L1 was positively expressed in 15 cases(17.0%)of ccRCC, and was significantly correlated with the late TNM staging, high Furhman grading, venous tumor emboli and distant metastasis.B7-H3 was positively expressed in 21 cases(23.9%)of tumor cells and 82 cases(93.2%)of tumor vascular endothelial cells, while 26.1%, 25% and 42.0% of tumor blood vessels showed localized, moderate and diffuse expression, respectively.The expression of B7-H3 in both tumor cells and vascular endothelial cells was significantly correlated with the poor invasive characteristics of the tumor.Conclusion B7-H3 is more highly expressed than PD-L1 in ccRCC, and is widely expressed in tumor blood vessels, and is closely related to the progression of ccRCC.B7-H3 may be a potential therapeutic predictor and multipathway therapeutic target.

参考文献/References:

[1] Okazaki T, Chikuma S, Iwai Y, et al.A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application [J].Nat Immunol,2013, 14(12): 1212-1218.
[2] Robert C, Schachter J, Long G V, et al.Pembrolizumab versus ipilimumab in advanced melanoma [J].N Engl J Med, 2015, 372(26): 2521-2532.
[3] Reck M, Rodríguez-Abreu D, Robinson A G, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J].N Engl J Med, 2016, 375(19): 1823-1833.
[4] Escudier B, Motzer R J, Tannir N M, et al.Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in checkmate 214 [J/OL].Eur Urol,(2019-11-13)[2020-02-20].http://www.ncbi.nlm.nih.gov/pmc/. DOI:10.1016/j.eururo.2019.10.025
[5] Wang L, Kang F B, Shan B E, et al.B7-H3-mediated tumor immunology: Friend or foe?[J].Int J Cancer, 2014,134(12): 2764-2771.
[6] Inamura K, Yokouchi Y, Kobayashi M, et al.Tumor B7-H3(CD276)expression and smoking history in relation to lung adenocarcinoma prognosis [J].Lung Cancer, 2017, 103:44-51.
[7] Yonesaka K, Haratani K, Takamura S, et al.B7-H3 nega-tively modulates CTL-mediated cancer immunity [J].Clin Cancer Res, 2018, 24(11): 2653-2664.
[8] Crispen P L, Sheinin Y, Roth T J, et al.Tumor cell and tumor vasculature expression of b7-h3 predict survival in clear cell renal cell carcinoma [J].Clin Cancer Res, 2008, 14(16): 5150-5157.
[9] Thompson R H, Kuntz S M, Leibovich B C, et al.Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up [J].Cancer Res, 2006, 66(7): 3381-3385.
[10] Thompson R H, Gillett M D, Cheville J C, et al.Costimula-tory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma [J].Cancer, 2005, 104(10):2084-2091.
[11] Ribas A.Tumor immunotherapy directed at PD-1 [J].N Engl J Med, 2012, 366(26): 2517-2519.
[12] Choueiri T K, Figueroa D J, Fay A P,et al.Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from comparz, a randomized controlled trial [J].Clin Cancer Res, 2015, 21(5):1071-1077.
[13] Mischinger J, Fr?hlich E, Mannweiler S, et al.Prognostic value of B7-H1, B7-H3 and the SSIGN score in metastatic clear cell renal cell carcinoma [J].Cent European J Urol, 2019, 72(1): 23-31.
[14] Castellanos J R, Purvis I J, Labak C M, et al.B7-H3 role in the immune landscape of cancer [J].Am J Clin Exp Immunol, 2017, 6(4): 66-75.
[15] Patel S P, Kurzrock R.PD-L1 Expression as a predictive biomarker in cancer immunotherapy [J].Mol Cancer Ther, 2015, 14(4): 847-856.
[16] Brahmer J, Reckamp K L, Baas P, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J].N Engl J Med,2015, 373(2):123-135.

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金资助项目(2016J01493)
更新日期/Last Update: 2020-04-15